Dendritic Cell Vaccine and Cabozantinib for Kidney Cancer
This study is testing a combination treatment for newly diagnosed, non-metastatic clear cell kidney cancer. It involves an autologous (made from your own cells) dendritic cell vaccine and an oral drug called cabozantinib. The vaccine is given as shots into the skin, and cabozantinib is taken as a pill. Researchers want to see how well your immune system responds to this combination and to understand any side effects. You may be able to join if you have clear cell kidney cancer that hasn't spread, are at least 18 years old, and have a specific immune marker called HLA-A2+ if you receive the vaccine. The study aims to enroll 42 participants, but its current status is unclear.
- Study design
- This study plans to enroll 42 participants. It involves giving the vaccine and cabozantinib before surgery.
- What's involved
- You would receive the vaccine intradermally every two weeks for two doses, and take oral cabozantinib daily for 10 days, all before surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your immune response and safety will be monitored for up to 48 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Autologous Dendritic Cell Vaccine in Kidney Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jodi Maranchie, MD · PRINCIPAL_INVESTIGATOR · UPMC Department of Urology
- Walter Storkus, PhD · STUDY_DIRECTOR · University of Pittsburgh
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Probability of immune responseUp to 48 months
Proportion of HLA-A2+ ccRCC patients that exhibit improved peripheral blood CD8+ T cell responses against 3 or more vaccine-inclusive peptide epitopes (DLK1, EphA2, HBB, NRP1, RGS5, TEM1) after active vaccination with Type I-polarized autologous dendritic cell (αDC1) vaccine with concomitant oral cabozantinib (IFN-γ ELISPOT).
- Safety profile of interventional therapy - Adverse EventsUp to 48 months
Proportion of patient reported symptoms and Dose Limiting Toxicities (DLT) for specific adverse events per NCI CTCAE v5.0.
- Safety profile of interventional therapy - reduction in CD31+Up to 48 months
Proportion of RCC patients that exhibit greater than 30% reduction in CD31+ blood vessel content from baseline biopsy.
- Reduction in tumor vascularityBaseline; Up to 48 months
Proportion of RCC patients that exhibit greater than 30% reduction in CD31+ blood vessel content from baseline biopsy.